|
Published by: SMI Publishing, Ltd
Published: Nov. 20, 2006
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Martin Braddock, Director Discovery Bioscience, AstraZeneca.
- 9.10 POTENTIAL ANTI-INFLAMMATORY DRUGS
- Establishing proof of concept for novel molecules
- The early development process
- Building close alliances with project teams, discovery and experimental medicine
- The common and not so common pitfalls
- The next steps
- Dr Lisa Marshall, Senior Director, Early Development & Team Leader, Compound Development, Johnson & Johnson.
- 9.50 SELECTIVE AND NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
- Can they be improved?
- Oxidative and nitrosative stress
- Nitric oxide donors
- In vivo and in vitro models
- NO-cox-2’s, CINODs
- Dr Gordon Letts, Senior Vice President, Research & Development & Chief Scientific Officer, NitroMed .
- 10.30 Morning Coffee
- 10.50 MODELS OF INFLAMMATION
- In vivo models of inflammation and inflammatory disease
- Traditional inflammation animal models
- Links to modern mechanistic knowledge
- Priorities: disease target or molecular target?
- Choosing the correct model for the target
- The way forward
- Dr Michael Seed, Senior Lecturer, William Harvey Research Institute.
- 11.30 A NOVEL ANTI-INFLAMMATORY MECHANISM WITH BROAD THERAPEUTIC UTILITY IN CHRONIC INFLAMMATORY DISEASES
- Novel highly selective kinase inhibitors will be discussed that suppress proinflammatory cytokines like TNF-a
- The compounds have good oral bioavailability and may represent a novel class of oral DMARDs
- The effects of these kinase inhibitors in various in vitro cellular assays and in vivo disease models of pain and inflammation will be described
- The potential of these kinase inhibitors for treatment of pain and chronic inflammatory diseases will be outlined
- Dr Steven Gilman, President & Chief Executive Officer, ActivBiotics.
- Dr Klaus Dembowsky, VP, Drug Discovery, Ingenium Pharmaceuticals AG.
- 12.50 Networking Lunch
- 2.10 TARGETS FOR SMALL MOLECULES AND THEIR MECHANISM OF ACTION
- Traditional and novel approaches
- The role of medicinal chemistry
- Ecosanoids synthesis
- Modulation of the prostaglandin synthesis by COX- and PGES- inhibitors
- Modulation of leukotriene synthesis by 5-LOX inhibitors and FLAP-antagonists
- Modulation of eicosanoids by phospholipase A2 inhibitors
- Leukotriene receptor antagonists
- New directions for anti-inflammatory drug targets and actions
- Dr Wolfgang Albrecht, Head, Drug Research, Merckle.
- 2.50 LATEST ADVANCES IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA)
- Development of a small molecule IKK2 inhibitor as novel therapy for rheumatoid arthritis
- Reviewing the drug discovery process
- Scientific rational and target validation
- Lead molecule pharmacological profile
- Biomarker discovery and development
- Strategies in drug development
- A look to the future in rheumatoid arthritis therapeutics
- Dr Yajun Xu, Director, Millennium Pharmaceuticals.
- 3.30 Afternoon Tea
- 4.00 NOVEL ANTI-INFLAMMATORY THERAPEUTIC STRATEGIES FOR TREATING CHRONIC INFLAMMATORY AND NEURODEGENERATIVE DISEASES
- The role of inflammation in Alzheimers disease, dementia, multiple sclerosis and others
- Traditional treatments
- Newly evolving cellular and molecular targets for potential therapies
- The role of cytokines, oxyradicals, ecosanoids and docosanoids in neurodegeneration
- Regulation of nitric oxide synthases, nitric oxode/peroxynitrite generation in microvascular functions
- Biomarker discoveries
- The latest developments in anti-inflammatory therapeutics
- Professor Kim Rainsford, Emeritus Professor of Biomedical Sciences, Sheffield Hallam University.
- 4.40 INFLAMMATORY PAIN
- Novel approach to inflammatory/neuropathic pain
- The pharmacology of inflammatory pain
- Small molecule approaches - IMiDs
- Biology of IMiDs
- Animal models and human studies
- Results and the implications for future research and therapeutics
- Dr David Stirling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene Corp.
- Sai Shankar, Research Scientist II, Celgene Corp.
- 5.20 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Richard Griffiths, Director, Licensing & Development, Pfizer.
- 9.10 INFLAMMATORY DRUG LICENSING
- Doing the deal and overcoming challenges
- The groundwork - what preparation to do before you license?
- Confidentiality and competition, the legal obligations
- Inward licensing, outward licensing and evaluation opportunities
- Minimising the financial risk
- Important steps to take after the deal is made
- Dr Richard Griffiths, Director, Licensing & Development, Pfizer.
- 9.50 NOVEL SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS AS ANTI-INFLAMMATORY AGENTS
- New research
- Chemical genomic drug discovery
- Structure-based design
- Potency, selectivity and efficacy profiles
- Biological profile and anti-inflammatory properties
- Therapeutic status and future potential
- Dr Ronald Magolda, Vice President, Medicinal Chemistry, Wyeth Research, Research Information.
- 10.30 Morning Coffee
- 11.00 MODULATION OF T REGULATORY CELLS
- A means of controlling inflammatory diseases
- The role of T reg cells in the immune system
- Natural and inducible T reg in controlling inflammatory disease
- Can we modulate the activity of T reg?
- Pathogen derived molecules as novel immunomodulatory agents
- Professor Neil Williams, Professor of Immunology, University Of Bristol.
- 11.40 CHEMOKINE RECEPTOR ANTAGONISTS
- Positive clinical efficacy
- What is the future of anti-inflammatory therapeutics targeted to chemokine receptors?
- Novel research
- What is the association between chemokine receptor antagonists and inflammatory disease?
- Clinical trials data and analysis
- The future of anti-inflammatory therapeutics?
- Dr William Hipkin, Senior Principal Scientist, Schering Plough.
- 12.20 Networking Lunch
- 1.30 THE USE OF IMMUNOMODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES
- Research and future implications
- An overview of immunomodulators and their therapeutic profile
- Preclinical and clinical data supporting their use in inflammatory disease
- Adverse event profiles and other limitations
- Targeting the lesion - can we improve selectivity?
- Strategies for the future - small molecular weight compounds
- Dr Cliff Whelan, Director, Phlogopharm.
- 2.50 INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM
- A look at Chronic Obstructive Pulmonary Disease (COPD) - research at AstraZeneca
- Presentation, pathogenesis and patient needs
- Current therapies and hopes for the future
- Glucocorticosteroids: room for improvements?
- Anti-cytokine and anti-chemokine therapies: the "new kids on the block"?
- Antisense therapies and oligonucleotides: a real option?
- Phosphodiesterase-IV inhibitors: the same old same old?
- Fresh research strategies and potential future therapies
- Dr Alan Young, Associate Director & Principal Scientist, Astrazeneca .
- 3.10 Afternoon Tea
- 4.00 ANTI-INFLAMMATORY MEDICINES FOR CHRONIC OBSTRUCTIVE LUNG DISEASES
- Discussing the challenges in development
- Inflammation, COPD vs asthma
- Biomarkers of inflammatory lung disease
- Preclinical models of COPD and asthma
- Modes of delivery
- Targets of anti-inflammatory drugs and therapy - discussing cytokines, PDE4, etc
- Dr David Rubin, Associate Director, Global Research and Development, 200/222, Pfizer.
- 4.40 MORE INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM
- Asthma - from the AstraZeneca perspective
- Presentation and pathogenesis
- Current therapies and the mechanism of action
- Glucocorticoides
- Anti-leukotrienes and 5-lioxygenase inhibitors
- Anti-cytokine and anti-chemokine therapies
- Antisense therapies and oligonucleotides
- Phosphodiesterase-IV
- Prospects for existing and new combination therapies
- Fresh research strategies and potential future therapies
- Dr Ash Bahl, Principal Scientist, Astrazeneca .
- 5.00 Chairman’s Closing Remarks and Close of Conference
AbstractSMi’s conference ‘Advances in Anti-Inflammatory Therapeutics - Novel Target Candidates for Inflammatory Conditions’ will launch discussions on the latest innovations and research into new drug targets and therapeutic strategies through plenary lectures and case studies. Providing a forum where technological advances and new applications in drug discovery can be reviewed, join world leaders in the provision of the latest therapeutics and insights into the production of more efficient, safe anti-inflammatory drugs.
Hear contributions from leading industry experts, including:
- Dr Ronald Magolda, Vice President, Medicinal Chemistry, Wyeth
- Dr Lisa Marshall, Senior Director, Early Development & Team Leader, Compound Development, Johnson & Johnson
- Dr Martin Braddock, Director, Discovery Bioscience, AstraZeneca
- Dr Richard Griffiths, Director, Licensing & Development, Pfizer
- Dr Alan Young, Associate Director, & Senior Principal Scientist, AstraZeneca
- Dr David Rubin, Associate Director, Global Research & Development, Pfizer
- Dr David Sterling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene
- Dr Yajun Xu, Director, Biochemistry & Cell Signalling, Inflammation, Millennium Pharmaceuticals
- Dr William Hipkin, Senior Principal Scientist, Schering-Plough
- Professor Kim Rainsford, Emeritus Professor, Biomedical Sciences, Sheffield Hallam University
Key issues that will be addressed at the conference include:
- Mechanism of action: Discover the novel action of the latest molecules and how this will influence the future anti-inflammatory drug market
- Novel anti-inflammatory therapeutics: Discuss the latest research, development and market expansion of anti- inflammatory therapeutics
- Case studies: Hear from leading industry experts as they discuss the latest treatment strategies for inflammatory diseases and how the industry may evolve
- Legislative considerations: Learn how to overcome the challenges associated with licensing your drug
- Information interchange: Interact and debate with some of the industry’s key experts and learn from their experience and expertise
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
